Abstract
Almost 10 years after the discovery of Orphanin FQ / Nociceptin (OFQ/N) a large number of synthetic small molecule agonists and antagonists have been developed and tested in various physiological assays. Together with the academic work on the physiological functions of OFQ/N, we now have compelling evidence that this neuropeptide system might represent a valuable target for the development of drugs treating a variety of psychiatric disorders. Most prominently, the anti-stress and anxiolytic effects of OFQ/N agonists have been investigated although clinical trials have not yet been launched. Other possible applications of OFQ/N agonists and antagonists include treatment of depression, anorexia and rewarding aspects of drug addiction. This paper will summarize current developments and highlight the scientific achievements that have been made to elucidate the functions of OFQ/N with respect to psychiatric disorders.
Keywords: Orphanin FQ, nociceptin, neuropeptide, anxiety, stress, depression, obesity, anorexia, drug abuse, reward
CNS & Neurological Disorders - Drug Targets
Title: The Orphanin FQ / Nociceptin Receptor as a Novel Drug Target in Psychiatric Disorders
Volume: 5 Issue: 2
Author(s): Rainer K. Reinscheid
Affiliation:
Keywords: Orphanin FQ, nociceptin, neuropeptide, anxiety, stress, depression, obesity, anorexia, drug abuse, reward
Abstract: Almost 10 years after the discovery of Orphanin FQ / Nociceptin (OFQ/N) a large number of synthetic small molecule agonists and antagonists have been developed and tested in various physiological assays. Together with the academic work on the physiological functions of OFQ/N, we now have compelling evidence that this neuropeptide system might represent a valuable target for the development of drugs treating a variety of psychiatric disorders. Most prominently, the anti-stress and anxiolytic effects of OFQ/N agonists have been investigated although clinical trials have not yet been launched. Other possible applications of OFQ/N agonists and antagonists include treatment of depression, anorexia and rewarding aspects of drug addiction. This paper will summarize current developments and highlight the scientific achievements that have been made to elucidate the functions of OFQ/N with respect to psychiatric disorders.
Export Options
About this article
Cite this article as:
Reinscheid K. Rainer, The Orphanin FQ / Nociceptin Receptor as a Novel Drug Target in Psychiatric Disorders, CNS & Neurological Disorders - Drug Targets 2006; 5 (2) . https://dx.doi.org/10.2174/187152706776359628
DOI https://dx.doi.org/10.2174/187152706776359628 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Current Stem Cell Research & Therapy Protein Amyloidogenesis Investigated by Small Angle Scattering
Current Pharmaceutical Design Integrating Pathophysiology in Migraine: Role of the Gut Microbiome and Melatonin
Current Pharmaceutical Design Quantum Dots Functionalized with Photo- or Redox-Active Species for Luminescence Sensing and Switching
Current Physical Chemistry Metabolic Syndrome the Gynecologist’s Approach
Current Women`s Health Reviews Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets P-Glycoprotein - Implications of Metabolism of Neoplastic Cells and Cancer Therapy
Current Cancer Drug Targets Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design Emerging Restorative Treatments for Parkinsons Disease: Manipulation and Inducement of Dopaminergic Neurons from Adult Stem Cells
CNS & Neurological Disorders - Drug Targets Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels
Recent Patents on Anti-Infective Drug Discovery Vagus nerve stimulation in treating depression: A tale of two stories.
Current Molecular Medicine Nuances in Alzheimer’s Genetic Risk Reveal Differential Predictions of Non-demented Memory Aging Trajectories: Selective Patterns by APOE Genotype and Sex
Current Alzheimer Research Patent Selections
Recent Patents on Nanotechnology Simulation of Microgravity for Studies in Gravitational Biology: Principles, Devices and Applications
Current Biotechnology An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness
Current Neurovascular Research Synthesis of 2, 3-Disubstituted-Quinazolin-4-(3H)-ones
Mini-Reviews in Medicinal Chemistry Analgesic Effects of Huwentoxin-IV on Animal Models of Inflammatory and Neuropathic Pain
Protein & Peptide Letters A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer’s Disease
Current Clinical Pharmacology